A phase I/II trial of OXB 102 for treatment of Parkinson's disease

Trial Profile

A phase I/II trial of OXB 102 for treatment of Parkinson's disease

Planning
Phase of Trial: Phase I/II

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Parkinson's disease gene therapy (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Mar 2017 According to an Oxford BioMedica media release, the company has been working on appropriate regulatory approvals for this planned three cohort Phase I/II study to be conducted in Cambridge and London, UK and Paris, France.
    • 18 Mar 2015 The title is not official. Trial focus assumed.
    • 18 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top